Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphoma.

Lenalidomide in non-Hodgkin lymphoma: biological effects of lenalidomide in lymphoma are synergistically enhanced with chemotherapy.

The role of lenalidomide in the postchemotherapy setting is also being explored.

How does Revlimid work for lymphoma?
What is the treatment for T-cell lymphoma?
What is the best treatment for non-Hodgkin's lymphoma?
What is the primary treatment for non-Hodgkin's lymphoma?

Lenalidomide Therapy for Patients With Relapsed and/or Refractory Peripheral T-Cell Lymphoma:
The purpose of this study is to: assess the effectiveness of lenalidomide for the treatment of patients with relapsed and/or refractory peripheral T-cell lymphoma; and, assess the safety of lenalidomide. Peripheral T-cell lymphomas (PTCLs) represent a subgroup of non-Hodgkin's lymphomas with poor prognostic features.

Final Report of a Phase 2 Clinical Trial of Lenalidomide:
Recent advances in the treatment of peripheral T-cell lymphoma indicate that lenalidomide may play a role in the management of this disease.
Lenalidomide in Adult T-Cell Leukemia/Lymphoma | Journal...
Oct 03, 2016 - Lenalidomide is a fairly well tolerated oral therapy with known CNS penetration; this is a promising option for these patients who often have poor performance status and are at high risk of CNS involvement. 14, 15 For these reasons, lenalidomide has now been added to the National Comprehensive Cancer Network guidelines for ATLL. 16
Cited by: 2
Aucoin, Weh K, Kohler-Mattis, Steven M, Horowitz
Published Year: 2016

The Emerging Role of Lenalidomide in the Management of...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573391
Based on preclinical studies and early clinical studies conducted in parallel to clinical trials, lenalidomide has
Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas

Emanuele Concini, Alberto Fabbri, Bianca Moretti, Monica Rocchia

Abstract

T-cell lymphomas (TCL) represent a group of lymphoid neoplasms characterised by an aggressive clinical course, even after an anthracycline-containing regimen. Novel agents for patients with relapsed/refractory TCL are urgently needed. Lenalidomide is an oral
Role of lenalidomide in the treatment of peripheral T-cell non-Hod

Lenalidomide in Adult T-Cell Leukemia/Lymphoma | Journal ...
Oct 03, 2016 - Lenalidomide is a fairly well-tolerated oral therapy with known CNS penetration; this is a promising option for these patients who often have poor performance status and are at high risk of CNS involvement. 14, 15 For these reasons, lenalidomide has now been added to the National Comprehensive Cancer Network guidelines for ATLL. 16
Cited by: 3  Author: Neha Mehta-Shah, Steven M. Horwitz
Publish Year: 2016

The Emerging Role of Lenalidomide in the Management of ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573391
Based on preclinical models and early correlative studies conducted in parallel to clinical trials, lenalidomide has been found to enhance natural killer (NK)- and T-cell activity against tumor cells, alter the balance of pro- and anti-inflammatory cytokines in the tumor bed, inhibit angiogenesis, and, to a lesser degree, induce cell cycle arrest and apoptosis in cancer cells.
Cited by: 6  Author: Francisco J Hernandez-Izaituri, Sameer ...
Publish Year: 2011

People also ask

Is there such a thing as peripheral T cell lymphoma?
What are the subtypes of nodal T cell lymphoma?
Are there any new drugs for peripheral T cell lymphoma?
Why is γδ T cell lymphoma reclassified as cutaneous?

Lenalidomide in non-Hodgkin lymphoma: biological ...
https://ashpublications.org/blood/article/125/16/...